Baker Bros. Advisors Lp Buys MyoKardia Inc, Neurocrine Biosciences Inc, Audentes Therapeutics Inc, Sells Spark Therapeutics Inc, Array BioPharma Inc, Solid Biosciences Inc

• New Purchases: AXSM, DERM, MGNX, ACOR, PTGX, CTMX,
• Added Positions: ASND, MYOK, NBIX, BOLD, AMRN, CBAY, TCDA, INSM, APLS, LJPC, ARAV,
• Reduced Positions: GHDX, ONCE, ARRY, ABEO, CFRX, XNCR,
• Sold Out: SLDB, NVAX, GNMX, PRTO,

For the details of BAKER BROS. ADVISORS LP's stock buys and sells, go to https://www.gurufocus.com/guru/baker+bros.+advisors+lp/current-portfolio/portfolio

1. Seattle Genetics Inc (SGEN) - 51,049,760 shares, 24.17% of the total portfolio. Shares added by 0.01%
2. Incyte Corp (INCY) - 34,271,827 shares, 19.05% of the total portfolio. Shares added by 0.06%
3. BeiGene Ltd (BGNE) - 11,959,824 shares, 10.20% of the total portfolio.
4. Alexion Pharmaceuticals Inc (ALXN) - 8,558,068 shares, 7.48% of the total portfolio. Shares added by 0.03%
5. ACADIA Pharmaceuticals Inc (ACAD) - 39,713,842 shares, 6.89% of the total portfolio.

Baker Bros. Advisors Lp initiated holding in Axsome Therapeutics Inc. The purchase prices were between $2.63 and $16.34, with an estimated average price of $9.17. The stock is now traded at around $23.00. The impact to a portfolio due to this purchase was 0.11%. The holding were 1,200,000 shares as of .

Baker Bros. Advisors Lp initiated holding in Dermira Inc. The purchase prices were between $6.19 and $14.13, with an estimated average price of $8.29. The stock is now traded at around $10.31. The impact to a portfolio due to this purchase was 0.08%. The holding were 906,943 shares as of .

Baker Bros. Advisors Lp initiated holding in Macrogenics Inc. The purchase prices were between $11.11 and $25.6, with an estimated average price of $17.21. The stock is now traded at around $16.27. The impact to a portfolio due to this purchase was 0.04%. The holding were 302,600 shares as of .

Baker Bros. Advisors Lp initiated holding in Protagonist Therapeutics Inc. The purchase prices were between $6.5 and $13.77, with an estimated average price of $8.76. The stock is now traded at around $10.80. The impact to a portfolio due to this purchase was 0.03%. The holding were 403,893 shares as of .

Baker Bros. Advisors Lp initiated holding in Acorda Therapeutics Inc. The purchase prices were between $12.93 and $17.47, with an estimated average price of $15.03. The stock is now traded at around $11.28. The impact to a portfolio due to this purchase was 0.03%. The holding were 292,134 shares as of .

Baker Bros. Advisors Lp initiated holding in CytomX Therapeutics Inc. The purchase prices were between $9.5 and $19.16, with an estimated average price of $14.88. The stock is now traded at around $10.86. The impact to a portfolio due to this purchase was 0.01%. The holding were 194,377 shares as of .

Baker Bros. Advisors Lp added to a holding in MyoKardia Inc by 222.39%. The purchase prices were between $39.23 and $55.82, with an estimated average price of $46.05. The stock is now traded at around $47.52. The impact to a portfolio due to this purchase was 0.23%. The holding were 1,016,306 shares as of .

Baker Bros. Advisors Lp added to a holding in Neurocrine Biosciences Inc by 50.43%. The purchase prices were between $69.31 and $91.53, with an estimated average price of $83.53. The stock is now traded at around $78.89. The impact to a portfolio due to this purchase was 0.21%. The holding were 1,098,670 shares as of .

Baker Bros. Advisors Lp added to a holding in Audentes Therapeutics Inc by 88.39%. The purchase prices were between $21.32 and $39.54, with an estimated average price of $28.43. The stock is now traded at around $38.23. The impact to a portfolio due to this purchase was 0.2%. The holding were 1,715,183 shares as of .

Baker Bros. Advisors Lp added to a holding in Apellis Pharmaceuticals Inc by 60.00%. The purchase prices were between $12.81 and $19.82, with an estimated average price of $15.64. The stock is now traded at around $18.93. The impact to a portfolio due to this purchase was 0.02%. The holding were 313,725 shares as of .

Baker Bros. Advisors Lp added to a holding in La Jolla Pharmaceutical Co by 226.65%. The purchase prices were between $5.24 and $10.52, with an estimated average price of $6.55. The stock is now traded at around $6.57. The impact to a portfolio due to this purchase was 0.01%. The holding were 505,240 shares as of .

Baker Bros. Advisors Lp sold out a holding in Solid Biosciences Inc. The sale prices were between $7.19 and $32.37, with an estimated average price of $16.87.

Baker Bros. Advisors Lp sold out a holding in Novavax Inc. The sale prices were between $10.18 and $46.8, with an estimated average price of $31.97.

Baker Bros. Advisors Lp sold out a holding in Aevi Genomic Medicine Inc. The sale prices were between $0.19 and $0.77, with an estimated average price of $0.23.

Baker Bros. Advisors Lp sold out a holding in Proteon Therapeutics Inc. The sale prices were between $0.5 and $3.75, with an estimated average price of $2.84.